FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to pharmaceutics and medicine, and concerns using 5-(2,6-dimorpholin-4-ylpyrimidin-4-yl)-4-trifluoromethylpyridin-2-ylamine for treating the diseases dependent on the epidermal growth factor (EGFR), wherein the above disease represents non-small cell lung carcinoma.
EFFECT: preparing the composition for treating the diseases dependent on the epidermal growth factor.
9 cl, 2 dwg
| Title |
Year |
Author |
Number |
| APPLICATION OF IMIDAZOQUINOLINES FOR TREATMENT OF EGFR-DEPENDENT DISEASES OR DISEASES WITH AQUIRED RESISTANCE TO AGENTS BINDING MEMBERS OF EGFR FAMILY |
2008 |
- Garsija-Ehcheverrija Karlos
- Maira Sove-Mishel'
|
RU2481838C2 |
| COMBINATION OF PHOSPHATIDYL INOSITOL-3-KINASE (PI3K) INHIBITOR AND mTOR INHIBITOR |
2009 |
- Karlos Garsija-Ehcheverrija
- Sove-Mishel' Maira
|
RU2538683C2 |
| COMBINATION OF (A) PHOSPHOINOSITIDE-3-KINASE INHIBITOR AND (B) Ras/Raf/Mek PATHAWAY MODULATOR |
2009 |
- Garsija-Ehcheverrija Karlos
- Mera Sove-Mishel'
- St'Juart Darrin
- Vi S'Jusan
- Frich Kristine
- Nejdzhel Tobi
|
RU2508110C2 |
| USE OF 2-CARBOXAMIDE-CYCLOAMINO UREA DERIVATIVES IN TREATMENT OF EGFR-DEPENDENT DISEASES OR DISEASES WITH ACQUIRED RESISTANCE TO AGENTS TARGETED AT EGFR-FAMILY MEMBERS |
2011 |
- Brakhmann, Zaskia Mariya
- Fritch, Kristin
- Mera, Saver-Mishel
- Shnell, Kristian Rene
- Garsiya-Echeverriya, Karlos
|
RU2589695C2 |
| METHOD OF TREATING CANCER CARRYING EGFR MUTATIONS |
2007 |
|
RU2492864C2 |
| EGFR INHIBITOR COMPOUNDS |
2017 |
- Banker, Kevin Duejn
- Khuan, Piter Tsinkhua
- Abrakham, Sanni
- Pinchman, Dzhozef Robert
- Khopkins, Chad Deniel
- Sli, Debora Khelen
|
RU2751341C2 |
| PI-3 KINASE DOSAGE REGIME |
2013 |
- Khiravat Samit
- Massachezi Kristian
|
RU2630975C2 |
| NEW COMBINATION OF 3-[(3-{[4-(4-MORPHOLINYLMETHYL)-1N-PYRROL-2-YL]METHYLENE}-2-OXO-2,3-DIHYDRO-1N-INDOL-5-YL)METHYL]-1,3-THIAZOLIDINE-2,4-DIONE AND TYROSINE KINASE INHIBITOR EGFR |
2016 |
- Berbridzh Majkl
- Kattan Valeri
- Zhak-Beskon Anne
|
RU2695362C2 |
| COMBINATION OF EGFR INHIBITOR AND MEK INHIBITOR FOR USE IN TREATMENT OF NRAS MUTATED CANCER |
2015 |
- Cross Darren Anthony Edward
- Eberlein Catherine Anne
|
RU2683276C2 |
| TETRAHYDROFOLATES IN COMBINATION WITH EGFR INHIBITORS |
2013 |
- Gustavsson Bengt
- Karlsson Bern
|
RU2619335C2 |
